TXG — 10x Genomics, Inc.
$58.19
$-0.91 (-1.54%)
10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits.
Market Cap
$7.65B
Forward P/E
671.4x
52-Week Range
N/A
TXG Price History
Revenue vs. Net Income
$643M
Revenue · FY2025
Annual. Net margin is shown under each year.
Free Cash Flow
$130M
FCF · FY2025
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
-4.5%
ROCE · FY2025
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
4.2x
Assets ÷ liabilities · FY2025
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
0.9%
CapEx · FY2025
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
+3.6%
Dilution · FY2025
Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).
